Fusion Genomics Corporation Canada

Fusion Genomics Corp (FG) is a molecular diagnostic test  development company that is introducing diagnostic kits with companion analysis software that offer superior clinical information, faster turn-around-times and ease of use for hospitals and clinical laboratories. Fusion is the first of two companies in the world to bring a validated Next Generation Sequencing (NGS) diagnostic test complete with highly secure cloud based analytical service for childhood cancers (ChildSeq-RNA SRCT) into the clinic. This test was validated in the renowned medical testing facility at the Texas Children Hospital, Baylor College of Medicine.

FG is completing development of kits for facilitating absolute diagnosis of pediatric and adult blood cancers. In addition, FG has partnered with the Royal Tropical Institute (Dutch: Koninklijk Instituut voor de Tropen; KIT) a World Health Organization reference diagnostic laboratory for infectious diseases to design the next generation of assays for the detection of infectious diseases including drug-resistant forms of tuberculosis, influenza, hepatitis and hemorrhagic fevers including Ebola.

Year Founded
2013
Biotech Subsector
Medtech Subsector
Biotech Phase of Development
Medtech Phase of Development
Technology Overview

Fusion Genomics Corporation (FG) develops molecular diagnostic tests that utilize next-generation sequencing (NGS) technologies. All of FG’s tests can be used with any of the widely adopted NGS instruments on the market. Data is analyzed using FGF’s secure FusionCloud, providing diagnosis –enabling DNA sequence information to the clinician.

Most NGS based diagnostic efforts can be divided into two categories: 1) whole genome sequencing (WGS), where the entire DNA of an individual (or a pathogen) is sequenced, and 2) target-capture sequencing (TCS), where only diseased portions of DNA are sequenced. TCS produces 1000 times less data than WGS. The expensive computational resources required for analysis of WGS data prevents it from being adopted for routine clinical use. Therefore, TCS is more suitable and appealing in frontline diagnostic environments.

TCS uses either PCR or “DNA baits” as the underlying technology to “capture” disease-specific regions of the genome. PCR-based methods suffer from limitations described earlier. FG uses proprietary Quantum ProbesTM, an enhanced form of DNA baits, in all its tests. Quantum ProbesTM allow for nearly limitless expansion of genetic targets and rapid development of new tests as well as patentable techniques that are beyond the capacity of PCR. The superior advantage of Quantum ProbeTM, coupled with FusionCloud analysis and reporting, will drive the successful adoption of the tests. 

Alliance & Collaborations
Texas Children Hospital, Baylor College of Medicine (Houston, USA), British Columbia Centre for Disease Control (Vancouver, Canada), Royal Tropical Institute / Koninklijk Instituut voor de Tropen (Amsterdam, Netherlands)
Supporting Metrics or Evidence

The Fusion Genomics team published a very well received peer-reviewed publication which demonstrated that their technology was more sensitive, accurate, rapid and comprehensive than current industry standards such as PCR and FISH.  This study can be found at here.

Current Financing Needs

 $0.5-1M to complete seed round

Current Investors

Founders, board members, family and friends.

IP Status

Patent applications are pending.

Management Team Highlights

Fusion Genomics Corporation’s team has established expertise in next-generation sequencing, diagnostic test and software development, and information technology.

Mohammed Qadir, PhD., Chief Executive Officer and Chief Scientific Officer has over 17 years of research experience; the last 10 were at the British Columbia Cancer Agency. As part of his early training, he worked with world-renowned experts in genomics and drug development and is the co-inventor of the ChildSeq assay and ChildDecode.

Greg Stazyk, Chief Technical Officer has over 20 years of experience in senior positions in the IT industry. Mr. Stazyk was the IT lead for one of Canada’s largest bioinformatics computing platform at the BC Cancer Agency’s Genome Sciences Centre (GSC). Mr. Stazyk was the senior manager at PMC-Sierra Inc. responsible for its global computer systems operation.

Brian Kwok, VP of Product Development has close to 10 years of experience in molecular biology and genomic technologies including leading edge next-generation sequencing. Mr. Kwok has worked in combinatorial drug screening and led the development of the ChildSeq assay.

Dr. Poul Sorensen MD, PhD: Board member and clinical expert. Dr. Sorensen is a world-renowned pediatric pathologist and is the Johal Chair in Childhood Cancer Research at the University of British Columbia, as well as a professor in the Department of Pathology and a Senior Scientist at the BC Cancer Research Agency (Vancouver, Canada). Dr. Sorensen is also the Chair of the Translational Research committee of the Children’s Oncology Group.

Mohammed Qadir
Chief Scientific Officer 

Genrich

Genrich is a Multi-Family office founded and based in Long Beach California with additional offices in New York Toronto and London. The firm is looking to make equity and venture debt investments into companies in the life science space ranging from $2-$2 million over the lifetime of the investment often set up in tranches. Ideal candidates will be located 2 hours driving distance from one of the firm?s offices Boston and Chicago will also be considered. The firm is actively seeking new investment opportunities.
John Nelson
Managing Director 

Golden Seeds

Golden Seeds is an investment group that was founded in 25 and is headquartered in New York with other offices in Boston Silicon Valley and Texas. The group currently invests out of the Golden Seeds angel network and the Golden Seeds venture funds. The group has managed 3 venture funds that are Golden Seeds Fund LP Golden Seeds Fund 2 LP and Innovate New York LP Fund. The Golden Seeds angel network has 32 members of which 1 are life science investors. Golden Seeds invests in companies with a female founder or CEO or with women in other C-level positions or with at least 1% of equity owned by women. Golden Seeds prefers to invest in companies with a valuation under $5 million, the group?s first-round equity investments generally range from $ .25 million to $2 million. The group invests in companies based across the US and Canada.
Bill Whitaker
Managing Director Co-Chair Life Science Section 

Green Park & Golf Ventures

Green Park & Golf Ventures (GPG) is a family office based in Dallas Texas. The firm was founded in 211 and is focused on healthcare companies. The firm makes seed venture and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $1K to $1M per portfolio company. The firm generally acts as the lead investor and is open to invest in syndicates. The firm primarily invests in companies that are based in Texas but is open to opportunities across North America. The firm is actively seeking new investment opportunities.
Clay Heighten
Founding Partner 
JR Garcia
Principal 
Carl Soderstrom
Founding Partner 

Greenhouse Capital Partners United States

Greenhouse Capital Partner is a venture capital firm that was founded in 2006 and is based in Sausalito, California. The firm selectively makes equity investments into life science companies in seed stage and series A financing round, but it also provides growth equity to highly capital efficient companies that can achieve cash flow break-even within two years. The typical investment size ranges from $0.25 million to $2 million.The firm focuses on investments in US based companies.

Eric Desai
Principal 

H.I.G. BioVentures

H.I.G. BioVentures is the life science investment affiliate of H.I.G. Capital and has offices across the USA. H.I.G. BioVentures has assets under management of $4m and is investing from its second fund which closed at $268m in 212. The firm typically makes initial equity investments of $3-7m with the potential to invest up to $2m over the life of an investment. While most of H.I.G. BioVentures? portfolio companies are US-based the firm will consider opportunities worldwide.
Enoch Kariuki
Vice President 

HealthQuest Capital United States

Sofinnova Ventures was founded in 1974 and is based in Menlo Park, CA. The firm has approximately $1b of assets under management, and makes life science investments from two fund families; the main Sofinnova Ventures fund and Sofinnova HealthQuest Capital. Sofinnova Venture Partners IX closed at $500 million in 2014, and the debut HealthQuest fund closed at $110 million in 2014. The firm makes investments in the form of equity (preferred stock) and is an activist investor; the firm prefers to lead investments, take a board seat at its portfolio companies and be actively involved in company management. Sofinnova Ventures plans to make 4-6 new investments in life science companies in 2014. 

The Sofinnova Ventures main fund invests in biopharmaceuticals and typically makes initial investments of $5-15m, with the potential for a total investment of $15-30m. The fund invests in companies based in North America or Europe. 

HealthQuest Capital invests in non-biopharmaceutical life science and medtech companies and typically makes initial investments of $2-3m, with the potential for total investments of $5-6m. HealthQuest Capital is a venture growth fund focused on commercial-stage technologies, and only invests in companies headquartered in North America (particularly the US Southeast or West Coast).

Garheng Kong
Garheng Kong
Managing Partner 
Randy Scott
Randy Scott
LinkedIn logo Partner 

Hercules Technology Growth Capital Inc.

Hercules Technology Growth Capital is a Private Equity company founded in 23 Headquartered in Palo Alto California with additional offices in Boston Boulder New York and McLean. The firm manages an evergreen structure and primarily provides high-growth companies in the life science space with senior secured debt financing. The firm can allocate up to $5 million per investment. The firm is very flexible with deal structures that can be customized to help companies reach their key milestones. The firm primarily invests in companies headquartered in the US but has the ability to invest overseas as well.
Janice Borque
Managing Director Life Sciences 

Horizon Technology Finance United States

Horizon Technology Finance is a venture lending, investment and financial services management company that was founded in 2003 and is headquartered in Farmington, Ct with additional offices in Walnut Creek, CA and Reston, VA. The firm controls approximately $200 million in assets under management and look to provide senior or subordinate loans to companies in the range of $2 to $20 million dollars, and often syndicates much larger deals. The firm prefers to lead or co-lead investments that they are involved in and looks to be involved in 15 deals in the next 6-9 months. The firm provides capital to companies located throughout the United States and Canada.

Year Founded
2003
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Jerry Michaud

Hub Angels Investment Group

Hub Angels Investment Group is an angel group that was founded in 2 and is based in Cambridge Massachusetts. The firm manages a fund structure and recently closed its 4th fund making the total AUM of the group around $4 million. The firm makes investments ranging from $25 to $5 in equity for companies that are at least 12 months old. The firm makes investments ranging from four to eight years and prefers to invest in companies whose valuation does not exceed $1 million. Hub angels plans on making approximately 3 allocations over the next 6-9 months with stated interest in diagnostics and medical device companies.
Randy Barko
Member